PLXDC1 Can Be a Biomarker for Poor Prognosis and Immune Evasion in Gastric Cancer

Xinwei Li,Yongfei Fan,Mingyue Tang,Huiyuan Li,Yue Zhang,Jiaqi Mi,Yanyan Wang,Menglin Zhao,Zishu Wang,Fang Su

DOI: https://doi.org/10.2147/jir.s383191

IF: 4.5

2022-09-17

Journal of Inflammation Research

Abstract:Xinwei Li, 1, &ast Yongfei Fan, 2, &ast Mingyue Tang, 1 Huiyuan Li, 1 Yue Zhang, 1 Jiaqi Mi, 1 Yanyan Wang, 1 Menglin Zhao, 1 Zishu Wang, 1 Fang Su 1 1 Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, 233004, People's Republic of China; 2 Department of Thoracic Surgery, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, 213003, People's Republic of China &astThese authors contributed equally to this work Correspondence: Fang Su; Zishu Wang, Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, 233004, People's Republic of China, Tel +86 13605523272; +86 13955254185, Email ; Background: Research has revealed that Plexin domain containing 1 (PLXDC1) is correlated with the prognosis of a variety of tumors, but its role in the tumor microenvironment (TME) of gastric cancer has not been reported. Methods: In this study, we analyzed PLXDC1 expression in gastric cancer using the Oncomine and the Cancer Genome Atlas (TCGA) databases and immunohistochemical staining experiments, and performed prognostic assessment with data from the TCGA and Kaplan–Meier Plotter databases. The immunomodulatory role of PLXDC1 in the gastric cancer TME was analyzed by signaling pathway enrichment, immune cell correlation analysis, immunomodulator risk model construction and immunohistochemical staining experiments of immune cells. Results: The results indicated that PLXDC1 was overexpressed in gastric cancer and that its overexpression was associated with poor prognosis. Multivariate Cox analysis revealed that PLXDC1 could be an independent biomarker of the risk of gastric cancer. Signaling pathway enrichment revealed that high PLXDC1 expression was involved in signaling pathways related to immune activation and stromal activation, and Tumor Immune Dysfunction and Exclusion (TIDE) assessment indicated that high PLXDC1 expression was associated with a significantly higher risk of immune evasion than low PLXDC1 expression. A Cox risk model based on PLXDC1-associated immunomodulators also presented poor prognosis, and immune evasion was significantly higher in the high-risk group than in the low-risk group. In addition, immunohistochemical staining of CD8/CD3/CD4 + T cells in the high and low PLXDC1 expression groups also observed immune cell distribution characteristics of immune evasion. Conclusion: This study analyzed PLXDC1 from multiple biological perspectives and revealed that PLXDC1 can be a biomarker for poor prognosis and immune evasion in gastric cancer. Graphical Keywords: PLXDC1, biomarker, tumor microenvironment, immune evasion, prognosis, immunotherapy Graphical Stomach cancer is one of the most common malignancies in the world and the fourth leading cause of cancer-related death. 1 According to the pathological staging of gastric cancer, stomach adenocarcinoma (STAD) accounts for 95% of all gastric cancer cases. 2 Patients diagnosed at an early stage with disease limited to the mucosa and submucosa and who undergo surgical treatment have five-year survival rates of 70% to 95%. 3 However, western surgical and population-based series show five-year survival rates of 20% to 30% for most patients with advanced tumors that have penetrated the submucosa. 4 Therefore, identifying effective biomarkers to help detect gastric cancer at an early stage and provide effective therapeutic targets is of great importance for patient prognosis. Immunotherapy is a landmark clinical approach for cancer treatment, and immunotherapy primarily functions by modulating the immune system to kill tumor cells. 5,6 Programmed death-ligand 1 (PD-L1)/programmed death-1 (PD-1) inhibitors, which are immune checkpoint inhibitors (ICIs), kill tumor cells by binding to PD-L1 on the surface of tumor cells or PD-1 on the surface of T cells to disrupt the ability of the tumor to evade the immune response. 7–10 Currently, immunotherapy has yielded promising results in the clinical treatment of non-small-cell lung cancer, providing a new direction for the treatment of gastric cancer and other malignant tumors. 11 However, with the application of immunotherapy in the clinic, researchers have found that only some patients benefit, and most patients do not have satisfactory responses to immunotherapy. 12 Tumor microenvironment (TME) refers to the surrounding microenvironment where tumor cells exist, including surrounding blood vessels, immune cells, fibroblasts, -Abstract Truncated-

immunology